newsfilter
← Latest News
Business Wire·

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7